Trial Profile

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR Clinical Study)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary) ; Docetaxel
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms PIONeeR

Most Recent Events

12 Sep 2024 According to the PIONeeR media release, data from the study will be presented at the upcoming ESMO Congress 2024, to be held September 13-17 in Barcelona, Spain, and virtually, during the Presidential Symposium III: Eyes to the future.
02 May 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
02 May 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com